Molecular genetics of premalignant oral lesions

Oral Diseases

Volumn 13, Issue 2, 2007, Pages 126-133

  Mithani, S K ^a   Mydlarz, W K ^a   Grumbine, F L ^a   Smith, I M ^a   Califano, J A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Erythroplakia; Leukoplakia; Lichen planus; Molecular genetics; Oral; Premalignant; Submucous fibrosis

Indexed keywords

KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOCHONDRIAL DNA; PROTEIN BCL 2; PROTEIN P53;

CANCER CLASSIFICATION; CANCER RISK; CARCINOGENESIS; CHROMOSOME 1; CHROMOSOME ABERRATION; CYTOGENETICS; DISEASE ASSOCIATION; EPIGENETICS; ERYTHROPLASIA; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEUKOPLAKIA; LICHEN PLANUS; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; MITOCHONDRIAL GENETICS; MOLECULAR GENETICS; MOUTH CARCINOMA; MOUTH DISEASE; MUTATION RATE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METHYLATION; REVIEW; RISK ASSESSMENT; SINGLE STRAND CONFORMATION POLYMORPHISM; SISTER CHROMATID; SQUAMOUS CELL CARCINOMA; TELOMERE; TUMOR SUPPRESSOR GENE; WORLD HEALTH ORGANIZATION;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; ERYTHROPLASIA; HUMANS; LEUKOPLAKIA, ORAL; LICHEN PLANUS, ORAL; MOLECULAR BIOLOGY; MOUTH NEOPLASMS; ORAL SUBMUCOUS FIBROSIS; PRECANCEROUS CONDITIONS;

EID: 33846949310     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2006.01349.x     Document Type: Review

References (103)

1. Bathi RJ, Prabhat (2003). p53 aberrations in oral sub mucous fibrosis and oral cancer detected by immunohistochemistry. Indian J Dent Res 14: 214-219.
2. Bouquot JE, Weiland LH, Kurland LT (1988). Leukoplakia and carcinoma in situ synchronously associated with invasive oral/oropharyngeal carcinoma in Rochester, Minn., 1935-1984. Oral Surg Oral Med Oral Pathol 65: 199-207.
3. Buser D, Rankin KV, Meier E, Plemons JM, Altermatt HJ, Rees TD (1997). Oral lichen planus. The clinical manifestations, histopathology, etiology, long-term course and patient data from the Stomatology Center at the Baylor College of Dentistry in Dallas, USA. Schweiz Monatsschr Zahnmed 107: 294-306.
4. Califano J, van der Riet P, Westra W et al (1996). Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488-2492.
5. Califano J, Westra WH, Meininger G, Corio R, Koch WM, Sidransky D (2000). Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 6: 347-352.
6. Cawson RA, Langdon JD, Eveson JW (1996). Surgical pathology of the mouth and jaws. Wright: Oxford, Boston.
7. Chang LY, Lin SC, Chang CS, Wong YK, Hu YC, Chang KW (1999). Telomerase activity and in situ telomerase RNA expression in oral carcinogenesis. J Oral Pathol Med 28: 389-396.
8. Chiba I, Muthumala M, Yamazaki Y et al (1998). Characteristics of mutations in the p53 gene of oral squamous-cell carcinomas associated with betel-quid chewing in Sri Lanka. Int J Cancer 77: 839-842.
9. Cox SC, Walker DM (1996a). Epithelial growth fraction and expression of p53 tumour suppressor gene in oral submucous fibrosis. Aust Dent J 41: 91-96.
10. Cox SC, Walker DM (1996b). Oral submucous fibrosis. A review. Aust Dent J 41: 294-299.
11. Critchley JA, Unal B (2003). Health effects associated with smokeless tobacco: a systematic review. Thorax 58: 435-443.
12. Cruz IB, Snijders PJ, Meijer CJ et al (1998). p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol 184: 360-368.
13. Cruz I, Napier SS, van der Waal I et al (2002a). Suprabasal p53 immunoexpression is strongly associated with high grade dysplasia and risk for malignant transformation in potentially malignant oral lesions from Northern Ireland. J Clin Pathol 55: 98-104.
14. Cruz I, Snijders PJ, Van Houten V, Vosjan M, Van der Waal I, Meijer CJ (2002b). Specific p53 immunostaining patterns are associated with smoking habits in patients with oral squamous cell carcinomas. J Clin Pathol 55: 834-840.
15. Curfman GD, Morrissey S, Drazen JM (2006). Expression of concern: Sudbo J et al DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 1270: 1278.
16. Daftary DK, ???? MP, Shah HT (1992). Reverse chutta smoking and palatal lesions. Control of tobacco-related cancers and oral diseases. In: Hi J, Gupta PC, Murti PR, eds. International symposium 1990. Oxford University Press: Bombay 11.
17. Dave BJ, Trivedi AH, Adhvaryu SG (1991). Variations in centromeric heterochromatin among patients with premalignant and malignant oral diseases. Int J Cancer 48: 386-389.
18. Dave BJ, Trivedi AH, Adhvaryu SG (1992). Role of areca nut consumption in the cause of oral cancers. A cytogenetic assessment. Cancer 70: 1017-1023.
19. Emilion G, Langdon JD, Speight P, Partridge M (1996). Frequent gene deletions in potentially malignant oral lesions. Br J Cancer 73: 809-813.
20. Fujimoto R, Kamata N, Yokoyama K et al (2001). Expression of telomerase components in oral keratinocytes and squamous cell carcinomas. Oral Oncol 37: 132-140.
21. Girod SC, Pape HD, Krueger GR (1994). p53 and PCNA expression in carcinogenesis of the oropharyngeal mucosa. Eur J Cancer B Oral Oncol 30B: 419-423.
22. Girod SC, Cesarz D, Fischer U, Krueger GR (1995). Detection of p53 and MDM2 protein expression in head and neck carcinogenesis. Anticancer Res 15: 1453-1457.
23. Gottlieb E, Tomlinson IP (2005). Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 5: 857-866.
24. Gupta PC, Mehta FS, Daftary DK et al (1980). Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol 8: 283-333.
25. Ha PK, Califano JA (2003). The molecular biology of mucosal field cancerization of the head and neck. Crit Rev Oral Biol Med 14: 363-369.
26. Ha PK, Califano JA (2006). Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 7: 77-82.
27. Ha PK, Pilkington TA, Westra WH, Sciubba J, Sidransky D, Califano JA (2002a). Progression of microsatellite instability from premalignant lesions to tumors of the head and neck. Int J Cancer 102: 615-617.
28. Ha PK, Tong BC, Westra WH et al (2002b). Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res 8: 2260-2265.
29. Ha PK, Benoit NE, Yochem R et al (2003). A transcriptional progression model for head and neck cancer. Clin Cancer Res 9: 3058-3064.
30. Hashibe M, Mathew B, Kuruvilla B et al (2000). Chewing tobacco, alcohol, and the risk of erythroplakia. Cancer Epidemiol Biomarkers Prev 9: 639-645.
31. Hittelman WN, Voravud N, Shin DM, Lee JS, Ro JY, Hong WK (1993). Early genetic changes during upper aerodigestive tract tumorigenesis. J Cell Biochem Suppl 17F: 233-236.
32. Hittelman WN, Kim HJ, Lee JS et al (1996). Detection of chromosome instability of tissue fields at risk: in situ hybridization. J Cell Biochem Suppl 25: 57-62.
33. Huang JS, Chiang CP, Kok SH, Kuo YS, Kuo MY (1997a). Loss of heterozygosity of APC and MCC genes in oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 26: 322-326.
34. Huang XF, Zhang WG, Song LJ, Fu HB (1997b). Immunohistochemical detection of PCNA and p53 protein in the premalignant lesions and squamous cell carcinomas of the oral mucosa. Shanghai Kou Qiang Yi Xue 6: 73-74.
35. Jayanthi V, Probert CS, Sher KS, Mayberry JF (1992). Oral submucosal fibrosis-a preventable disease. Gut 33: 4-6.
36. Jeng JH, Chang MC, Hahn LJ (2001). Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol 37: 477-492.
37. Jiang WW, Fujii H, Shirai T, Mega H, Takagi M (2001). Accumulative increase of loss of heterozygosity from leukoplakia to foci of early cancerization in leukoplakia of the oral cavity. Cancer 92: 2349-2356.
38. Jordan RC, Catzavelos GC, Barrett AW, Speight PM (1996). Differential expression of bcl-2 and bax in squamous cell carcinomas of the oral cavity. Eur J Cancer B Oral Oncol 32B: 394-400.
39. Kannan S, Tahara H, Yokozaki H et al (1997). Telomerase activity in premalignant and malignant lesions of human oral mucosa. Cancer Epidemiol Biomarkers Prev 6: 413-420.
40. Katta R (2000). Lichen planus. Am Fam Physician 61: 3319-3324, 3327-3328.
41. Kaur J, Srivastava A, Ralhan R (1994). Overexpression of p53 protein in betel- and tobacco-related human oral dysplasia and squamous-cell carcinoma in India. Int J Cancer 58: 340-345.
42. Kilpi A, Rich AM, Konttinen YT, Reade PC (1996). Expression of c-erbB-2 protein in keratinocytes of oral mucosal lichen planus and subsequent squamous cell carcinoma. Eur J Oral Sci 104: 278-284.
43. Kim J, Yook JI, Lee EH et al (2001). Evaluation of premalignant potential in oral lichen planus using interphase cytogenetics. J Oral Pathol Med 30: 65-72.
44. Kim MM, Clinger JD, Masayesva BG et al (2004). Mitochondrial DNA quantity increases with histopathologic grade in premalignant and malignant head and neck lesions. Clin Cancer Res 10: 8512-8515.
45. Kovesi G, Szende B (2003). Changes in apoptosis and mitotic index, p53 and Ki67 expression in various types of oral leukoplakia. Oncology 65: 331-336.
46. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH (1978). Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 46: 518-539.
47. Krutchkoff DJ, Eisenberg E (1985). Lichenoid dysplasia: a distinct histopathologic entity. Oral Surg Oral Med Oral Pathol 60: 308-315.
48. Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS (2005). Robbins and Cotran pathologic basis of disease. 7th edn. Elsevier Saunders: Philadelphia, PA.
49. Largey JS, Meltzer SJ, Sauk JJ, Hebert CA, Archibald DW (1994). Loss of heterozygosity involving the APC gene in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol 77: 260-263.
50. Lay KM, Sein K, Myint A, Ko SK, Pindborg JJ (1982). Epidemiologic study of 600 villagers of oral precancerous lesions in Bilugyun: preliminary report. Community Dent Oral Epidemiol 10: 152-155.
51. Lee JS, Kim SY, Hong WK et al (1993). Detection of chromosomal polysomy in oral leukoplakia, a premalignant lesion. J Natl Cancer Inst 85: 1951-1954.
52. Lee JJ, Hong WK, Hittelman WN et al (2000). Predicting cancer development in oral leukoplakia: 10 years of translational research. Clin Cancer Res 6: 1702-1710.
53. Liao J, Mitsuyasu T, Yamane K, Ohishi M (2000). Telomerase activity in oral and maxillofacial tumors. Oral Oncol 36: 347-352.
54. Liao PH, Lee TL, Yang LC, Yang SH, Chen SL, Chou MY (2001). Adenomatous polyposis coli gene mutation and decreased wild-type p53 protein expression in oral submucous fibrosis: a preliminary investigation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92: 202-207.
55. Lippman SM, Shin DM, Lee JJ et al (1995). p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 55: 16-19.
56. Liu CJ, Lee YJ, Chang KW, Shih YN, Liu HF, Dang CW (2004). Polymorphism of the MICA gene and risk for oral submucous fibrosis. J Oral Pathol Med 33: 1-6.
57. Lopez M, Aguirre JM, Cuevas N et al (2003). Gene promoter hypermethylation in oral rinses of leukoplakia patients-a diagnostic and/or prognostic tool? Eur J Cancer 39: 2306-2309.
58. Lopez M, Aguirre JM, Cuevas N et al (2004). Use of cytological specimens for p53 gene alteration detection in oral squamous cell carcinoma risk patients. Clin Oncol (R Coll Radiol) 16: 366-370.
59. Lumerman H, Freedman P, Kerpel S (1995). Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79: 321-329.
60. Luzar B, Poljak M, Marin IJ, Eberlinc A, Klopcic U, Gale N (2004). Human telomerase catalytic subunit gene re-expression is an early event in oral carcinogenesis. Histopathology 45: 13-19.
61. Mao L (1997). Leukoplakia: molecular understanding of premalignant lesions and implications for clinical management. Mol Med Today 3: 442-448.
62. Mashberg A, Meyers H (1976). Anatomical site and size of 222 early asymptomatic oral squamous cell carcinomas: a continuing prospective study of oral cancer. II. Cancer 37: 2149-2157.
63. van der Meij EH, Schepman KP, van der Waal I (2003). The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 96: 164-171.
64. Miyoshi Y, Tsukinoki K, Imaizumi T et al (1999). Telomerase activity in oral cancer. Oral Oncol 35: 283-289.
65. Murti PR, Bhonsle RB, Pindborg JJ, Daftary DK, Gupta PC, Mehta FS (1985). Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent Oral Epidemiol 13: 340-341.
66. Mutirangura A, Supiyaphun P, Trirekapan S et al (1996). Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res 56: 3530-3533.
67. Nishioka H, Hiasa Y, Hayashi I, Kitahori Y, Konishi N, Sugimura M (1993). Immunohistochemical detection of p53 oncoprotein in human oral squamous cell carcinomas and leukoplakias: comparison with proliferating cell nuclear antigen staining and correlation with clinicopathological findings. Oncology 50: 426-429.
68. Nylander K, Dabelsteen E, Hall PA (2000). The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med 29: 413-425.
69. O'Flatharta C, Leader M, Kay E et al (2002). Telomerase activity detected in oral lichen planus by RNA in situ hybridisation: not a marker for malignant transformation. J Clin Pathol 55: 602-607.
70. Ogmundsdottir HM, Hilmarsdottir H, Astvaldsdottir A, Johannsson JH, Holbrook WP (2002). Oral lichen planus has a high rate of TP53 mutations. A study of oral mucosa in iceland. Eur J Oral Sci 110: 192-198.
71. Parise O, Carvalho LV, Miguel RE, Kowalski LP (2004). Prognostic impact of p53, c-erbB-2 and epidermal growth factor receptor on head and neck carcinoma. Sao Paulo Med J 122: 264-268.
72. Partridge M, Emilion G, Pateromichelakis S, A'Hern R, Phillips E, Langdon J (1998). Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncol 34: 77-83.
73. Pindborg JJ, Wahi PN (1997). Histological typing of cancer and precancer of the oral mucosa. 2nd edn. Springer: Berlin; New York.
74. Pindborg JJ, Renstrup G, Poulsen HE, Silverman S Jr (1963). Studies in oral leukoplakias. V. Clinical and histologic signs of malignancy. Acta Odontol Scand 21: 407-414.
75. Pindborg JJ, Jolst O, Renstrup G, Roed-Petersen B (1968). Studies in oral leukoplakia: a preliminary report on the period prevalence of malignant transformation in leukoplakia based on a follow-up study of 248 patients. J Am Dent Assoc 76: 767-771.
76. Qin GZ, Park JY, Chen SY, Lazarus P (1999). A high prevalence of p53 mutations in pre-malignant oral erythroplakia. Int J Cancer 80: 345-348.
77. Regezi JA, Sciubba JJ (1993). Oral pathology: clinical-pathologic correlations. 2nd edn. Saunders: Philadelphia.
78. Reibel J (2003). Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 14: 47-62.
79. Reichart PA, Philipsen HP (2005). Oral erythroplakia-a review. Oral Oncol 41: 551-561.
80. Ries JC, Schreiner D, Steininger H, Girod SC (1998). p53 mutation and detection of p53 protein expression in oral leukoplakia and oral squamous cell carcinoma. Anticancer Res 18: 2031-2036.
81. Rosin MP, Cheng X, Poh C et al (2000). Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 6: 357-362.
82. Sanchez-Cespedes M, Parrella P, Nomoto S et al (2001). Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res 61: 7015-7019.
83. Scheifele C, Schlechte H, Bethke G, Reichart PA (2002). Detection of TP53-mutations in brush biopsies from oral leukoplakias. Mund Kiefer Gesichtschir 6: 410-414.
84. Schepman KP, van der Meij EH, Smeele LE, van der Waal I (1998). Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol 34: 270-275.
85. Shafer WG, Waldron CA (1975). Erythroplakia of the oral cavity. Cancer 36: 1021-1028.
86. Sierra J, Yoshida T, Joazeiro CA, Jones KA (2006). The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev 20: 586-600.
87. Silverman S Jr (2000). Oral lichen planus: a potentially premalignant lesion. J Oral Maxillofac Surg 58: 1286-1288.
88. Silverman S Jr, Gorsky M, Lozada F (1984). Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 53: 563-568.
89. Silverman S Jr, Gorsky M, Lozada-Nur F (1985). A prospective follow-up study of 570 patients with oral lichen planus: persistence, remission, and malignant association. Oral Surg Oral Med Oral Pathol 60: 30-34.
90. Silverman S Jr, Gorsky M, Lozada-Nur F, Giannotti K (1991). A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol 72: 665-670.
91. Sinor PN, Gupta PC, Murti PR et al (1990). A case-control study of oral submucous fibrosis with special reference to the etiologic role of areca nut. J Oral Pathol Med 19: 94-98.
92. Sudbo J, Kildal W, Johannessen AC et al (2002). Gross genomic aberrations in precancers: clinical implications of a long-term follow-up study in oral erythroplakias. J Clin Oncol 20: 456-462.
93. Sudbo J, Lippman SM, Lee JJ et al (2004). The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 350: 1405-1413.
94. Teni T, Pawar S, Sanghvi V, Saranath D (2002). Expression of bcl-2 and bax in chewing tobacco-induced oral cancers and oral lesions from India. Pathol Oncol Res 8: 109-114.
95. p21-22 early in head and neck cancer progression. Cancer Res 54: 1156-1158.
96. Warnakulasuriya KA, Tavassoli M, Johnson NW (1998). Relationship of p53 overexpression to other cell cycle regulatory proteins in oral squamous cell carcinoma. J Oral Pathol Med 27: 376-381.
97. Williams HK (2000). Molecular pathogenesis of oral squamous carcinoma. Mol Pathol 53: 165-172.
98. Youssef EM, Lotan D, Issa JP et al (2004). Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res 10: 1733-1742.
99. Yusuf H, Yong SL (2002). Oral submucous fibrosis in a 12-year-old Bangladeshi boy: a case report and review of literature. Int J Paediatr Dent 12: 271-276.
100. Zain RB, Ikeda N, Razak IA et al (1997). A national epidemiological survey of oral mucosal lesions in Malaysia. Community Dent Oral Epidemiol 25: 377-383.
101. Zain RB, Ikeda N, Gupta PC et al (1999). Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits: consensus from a workshop held in Kuala Lumpur, Malaysia, November 25-27, 1996. J Oral Pathol Med 28: 1-4.
102. Zhang L, Rosin MP (2001). Loss of heterozygosity: a potential tool in management of oral premalignant lesions? J Oral Pathol Med 30: 513-520.
103. Zhang L, Michelsen C, Cheng X, Zeng T, Priddy R, Rosin MP (1997). Molecular analysis of oral lichen planus. A premalignant lesion? Am J Pathol 151: 323-327.